
Kluwer Patent Blog

Leflunomid (Leflunomide), Federal Court of Justice (Bundesgerichtshof), 24 July 2012

Thorsten Bausch (Hoffmann Eitle) · Sunday, July 14th, 2013

and Bernd Kröger.

A combination of two pharmaceutical ingredients, i.e. leflunomide and teriflunomide is to be considered obvious if the person skilled in the art uses an obvious process to obtain leflunomide that automatically results in – even with a certain delay – both components due to a chemical reaction.

Click [here](#) for the full text of this case.

A summary of this case will be posted on <http://www.Kluweriplaw.com>

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change

This entry was posted on Sunday, July 14th, 2013 at 8:43 pm and is filed under [Case Law](#), [Chemical Engineering](#), [Germany](#), [Inventive step](#), [Novelty](#), [Validity](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.